Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

360 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Classification of Molecular Subtypes of High-Grade Serous Ovarian Cancer by MALDI-Imaging.
Kassuhn W, Klein O, Darb-Esfahani S, Lammert H, Handzik S, Taube ET, Schmitt WD, Keunecke C, Horst D, Dreher F, George J, Bowtell DD, Dorigo O, Hummel M, Sehouli J, Blüthgen N, Kulbe H, Braicu EI. Kassuhn W, et al. Among authors: horst d. Cancers (Basel). 2021 Mar 25;13(7):1512. doi: 10.3390/cancers13071512. Cancers (Basel). 2021. PMID: 33806030 Free PMC article.
Comparison of risk assessment in 1652 early ER positive, HER2 negative breast cancer in a real-world data set: classical pathological parameters vs. 12-gene molecular assay (EndoPredict).
Jank P, Lindner JL, Lehmann A, Pfitzner BM, Blohmer JU, Horst D, Kronenwett R, Denkert C, Schmitt WD. Jank P, et al. Among authors: horst d. Breast Cancer Res Treat. 2022 Jan;191(2):327-333. doi: 10.1007/s10549-021-06415-0. Epub 2021 Nov 16. Breast Cancer Res Treat. 2022. PMID: 34783927 Free PMC article.
Predictive biomarker for surgical outcome in patients with advanced primary high-grade serous ovarian cancer. Are we there yet? An analysis of the prospective biobank for ovarian cancer.
Keunecke C, Kulbe H, Dreher F, Taube ET, Chekerov R, Horst D, Hummel M, Kessler T, Pietzner K, Kassuhn W, Heitz F, Muallem MZ, Lang SM, Vergote I, Dorigo O, Lammert H, du Bois A, Angelotti T, Fotopoulou C, Sehouli J, Braicu EI. Keunecke C, et al. Among authors: horst d. Gynecol Oncol. 2022 Aug;166(2):334-343. doi: 10.1016/j.ygyno.2022.06.010. Epub 2022 Jun 21. Gynecol Oncol. 2022. PMID: 35738917
Prognostic value of regulatory T cells and T helper 17 cells in high grade serous ovarian carcinoma.
Marchenko S, Piwonski I, Hoffmann I, Sinn BV, Kunze CA, Monjé N, Pohl J, Kulbe H, Schmitt WD, Darb-Esfahani S, Braicu EI, von Brünneck AC, Sehouli J, Denkert C, Horst D, Jöhrens K, Taube ET. Marchenko S, et al. Among authors: horst d. J Cancer Res Clin Oncol. 2023 Jun;149(6):2523-2536. doi: 10.1007/s00432-022-04101-2. Epub 2022 Jun 28. J Cancer Res Clin Oncol. 2023. PMID: 35763108 Free PMC article.
Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.
Glajzer J, Castillo-Tong DC, Richter R, Vergote I, Kulbe H, Vanderstichele A, Ruscito I, Trillsch F, Mustea A, Kreuzinger C, Gourley C, Gabra H, Taube ET, Dorigo O, Horst D, Keunecke C, Baum J, Angelotti T, Sehouli J, Braicu EI. Glajzer J, et al. Among authors: horst d. Ann Surg Oncol. 2023 Jan;30(1):35-45. doi: 10.1245/s10434-022-12459-3. Epub 2022 Sep 9. Ann Surg Oncol. 2023. PMID: 36085390 Free PMC article.
Low Expression of RGS2 Promotes Poor Prognosis in High-Grade Serous Ovarian Cancer.
Ihlow J, Monjé N, Hoffmann I, Bischoff P, Sinn BV, Schmitt WD, Kunze CA, Darb-Esfahani S, Kulbe H, Braicu EI, Sehouli J, Denkert C, Horst D, Taube ET. Ihlow J, et al. Among authors: horst d. Cancers (Basel). 2022 Sep 23;14(19):4620. doi: 10.3390/cancers14194620. Cancers (Basel). 2022. PMID: 36230542 Free PMC article.
AHRR and SFRP2 in primary versus recurrent high-grade serous ovarian carcinoma and their prognostic implication.
Monjé N, Dragomir MP, Sinn BV, Hoffmann I, Makhmut A, Simon T, Kunze CA, Ihlow J, Schmitt WD, Pohl J, Piwonski I, Marchenko S, Keunecke C, Calina TG, Tiso F, Kulbe H, Kreuzinger C, Cacsire Castillo-Tong D, Sehouli J, Braicu EI, Denkert C, Darb-Esfahani S, Kübler K, Capper D, Coscia F, Morkel M, Horst D, Sers C, Taube ET. Monjé N, et al. Among authors: horst d. Br J Cancer. 2024 May;130(8):1249-1260. doi: 10.1038/s41416-023-02550-1. Epub 2024 Feb 9. Br J Cancer. 2024. PMID: 38361045 Free PMC article.
High Concordance of Different Assays in the Determination of Homologous Recombination Deficiency-Associated Genomic Instability in Ovarian Cancer.
Pfarr N, von Schwarzenberg K, Zocholl D, Merkelbach-Bruse S, Siemanowski J, Mayr EM, Herold S, Kleo K, Heukamp LC, Willing EM, Menzel M, Lehmann U, Bartels S, Chakraborty S, Baretton G, Demes MC, Döring C, Kazdal D, Budczies J, Rad R, Wild P, Christinat Y, McKee T, Schirmacher P, Horst D, Büttner R, Stenzinger A, Sehouli J, Vollbrecht C, Hummel M, Braicu EI, Weichert W; German HRD assay Harmonization Consortium. Pfarr N, et al. Among authors: horst d. JCO Precis Oncol. 2024 Mar;8:e2300348. doi: 10.1200/PO.23.00348. JCO Precis Oncol. 2024. PMID: 38513168 Free PMC article.
360 results